Napredna pretraga

Pregled bibliografske jedinice broj: 34122

Comparasion of chlortalidone, propranolol and bopindolol in six-month treatment of arterial hypertension


Bagatin, Jugoslav; Sardelić, Sanda; Pivac, Nediljko; Polić, Stojan; Ljutić, Dragan; Rakić, Drago; Naranča, Mario; Bojić, Lovro; Kovačić, Zdenko; Rumboldt, Zvonko
Comparasion of chlortalidone, propranolol and bopindolol in six-month treatment of arterial hypertension // International Journal of Clinical Pharmacology Research, 18 (1988), 73-78 (međunarodna recenzija, članak, znanstveni)


Naslov
Comparasion of chlortalidone, propranolol and bopindolol in six-month treatment of arterial hypertension

Autori
Bagatin, Jugoslav ; Sardelić, Sanda ; Pivac, Nediljko ; Polić, Stojan ; Ljutić, Dragan ; Rakić, Drago ; Naranča, Mario ; Bojić, Lovro ; Kovačić, Zdenko ; Rumboldt, Zvonko

Izvornik
International Journal of Clinical Pharmacology Research (0251-1649) 18 (1988); 73-78

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Chlortalidone; propranolol; bopindolol; arterial hypertension.

Sažetak
The aim of this study was to test the hypothesis that prolonged treatment of mild to moderate hypertension with low-dose thiazide diuretics or beta blockers does not induce any of the major untoward biochemical changes, such as hypertriglyceridemia, hypercholesterolemia, hyperuricemia and electrolyte imbalances. The effect of these drugs was analyzed in 100 outpatients (52 males and 48 females), aged 52.0 +/-7.9 years with mild to moderate hypertension in a prospective 6-month study. After an appropriate > work-up the patients were randomized to either 25 mg chlorthalidone (40 pts), 120 mg propranolol (30 pts) or 2 mg bopindolol (30 pts). A significant reduction by approximately 10% in systolic and diastolic blood pressure was recorded in all the groups. At the end of the 6th month in the chlorthalidone group trigycerides increased to 3.0+/-2.1 mmol/l from 2.8+/-1.6 mmol/l, while cholesterol after an initial increase to 6.6+/-1.6 from 6.4+/-1.6 mmol/l returned to the baseline level. Uricemia and serum potassium decreased by 4%. The body weight was reduced from 86.1+/-13.4 to 83.8+/-13.4 kg. There was no change in serum glucose level. In the propranolol group, as expected, heart rate decreased by 20% but there were no significant changes in glucose or potassium plasma concentrations. Triglycerides did not change significantly, while cholesterol after a small increase returned to the initial levels. Similar results were obtained in the bopindolol group, apart from the triglycerides which increased significantly (to 2.5+/-1.1 from 2.2+/-0.4 mmol/l), probably because of the lower baseline concentration. We conclude that in prolonged teratment chlorthalidone, propranolol and bopindolol do not induce significant untoward biochemical changes that alone might increase cardiovascular risk.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE